USFDA concludes inspection at Shilpa Medicare Raichur unit
Karnataka: Shilpa Medicare has announced that the United States Food and Drug Administration (USFDA) has conducted an inspection at Unit-2 of Shilpa Pharma Lifesciences Limited, a wholly owned subsidiary of the Company, located at Raichur.
The inspection was held from March 10-14, 2025.
The inspection was closed with ZERO observations.
This is second consecutive ZERO 483 inspection from USFDA at this site.
Read also: Shilpa Medicare Gets CDSCO Panel Nod for Novel NAFLD Drug, Advances to Marketing Approval Stage
Shilpa Medicare is an integrated pharmaceutical group with a strong presence in niche oncology and non-oncology active pharmaceutical ingredients (APIs), peptides, polymers, and differentiated finished dosage formulations. The company is also committed to providing end-to-end Contract Development and Manufacturing Organization (CDMO) services to global pharmaceutical companies. Shilpa Medicare operates four R&D units and seven manufacturing facilities, ensuring robust research and manufacturing capabilities.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.